Astellas Pharma Inc (OTCPK:ALPMY)
$ 9.72 -0.18 (-1.82%) Market Cap: 17.43 Bil Enterprise Value: 21.25 Bil PE Ratio: 4,243.06 PB Ratio: 1.82 GF Score: 77/100

Astellas Pharma Inc R&D Meeting Transcript

Mar 09, 2022 / 12:30AM GMT
Release Date Price: $15.68 (-2.37%)
Ikuno Fujii
Astellas Pharma Inc. - Head of Corporate Advocacy & Relation

[Interpreted] Thank you very much for your participation, and (inaudible) meeting as part of your busy schedule. I'm Fujii, Corporate Advocacy Relations. Thank you very much. For this meeting live streaming or telephone conference participations are available. We make presentation first, and the Q&A session will follow. The questions accepted only from the telephone. You cannot ask questions through live streaming.

The website, you can find a slide package, and that is what we are going to use for this meeting. So if you participate through the telephone, please have it with you. The participants for today, Representative Director, President and CEO, Kenji Yasukawa; Corporate Executive Vice President, Chief Strategy Officer, Chief Business Officer; Naoki Okamura; Chief Medical Officer, Bernie Zeiher; Chief Scientific Officer; Yoshitsugu Shitaka; Division Head of Gene Therapy Research and Technical Operations; Head, Mathew Pletcher. 5 of them in total and Bernie Zeiher and Mathew Pletcher are participating here

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot